Omda

Omda is the current name of what was CSAM Health Group until a 2023 rename — the Norwegian Business Register's own history for the entity shows it was registered in 2012 as CSAM Invest AS, renamed CSAM Health Group AS in 2020 and Omda AS in 2023.

The product line is specialist rather than general-purpose: Cytodose for oncology treatment planning, laboratory information management, connected imaging, maternity and fertility software, and emergency response systems, sold to hospitals that already run a general EHR and need depth in one department.

That specialism is the actual pitch. A general hospital information system treats oncology as one module among many; Omda's Cytodose is built only for chemotherapy dosing and treatment planning, which is the kind of depth a department buys as a second system rather than expects from its EHR vendor.

Omda AS is headquartered in Oslo and holds ISO 13485:2016 certification, the quality-management standard for medical device software, which matters for treatment-planning software specifically. Norway is in the EEA and fully inside the GDPR though outside the EU itself. Pricing is enterprise and quoted, and the company's history of renames is worth knowing before searching for "CSAM" and finding an old product page.

What Omda does well

• ISO 13485:2016 certified, relevant for treatment-planning software
• Deep specialist modules: oncology, LIMS, imaging, maternity
• Norwegian company, EEA and GDPR jurisdiction
• Sold as a department-level complement to an existing EHR
• Continuous operating history since 2012 under different names

Where Omda falls short

• Norway is EEA, not EU
• Renamed twice (CSAM Invest, CSAM Health Group, now Omda), which complicates research
• Pricing not published
• Specialist modules rather than a general hospital record

Standout feature. Cytodose treats only oncology dosing, which is the depth a cancer department needs and a general EHR rarely has.